Compare MIRM & GTLB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MIRM | GTLB |
|---|---|---|
| Founded | 2018 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7B | 4.7B |
| IPO Year | 2019 | 2021 |
| Metric | MIRM | GTLB |
|---|---|---|
| Price | $107.23 | $26.37 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 27 |
| Target Price | ★ $119.85 | $37.17 |
| AVG Volume (30 Days) | 637.7K | ★ 6.6M |
| Earning Date | 05-06-2026 | 06-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 74.59 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $19,138,000.00 | ★ $955,224,000.00 |
| Revenue This Year | $26.22 | $18.72 |
| Revenue Next Year | $22.04 | $16.05 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 25.81 |
| 52 Week Low | $47.89 | $18.73 |
| 52 Week High | $114.99 | $52.38 |
| Indicator | MIRM | GTLB |
|---|---|---|
| Relative Strength Index (RSI) | 64.97 | 45.13 |
| Support Level | $87.93 | $19.71 |
| Resistance Level | $107.51 | $34.06 |
| Average True Range (ATR) | 4.13 | 1.76 |
| MACD | 1.17 | -0.65 |
| Stochastic Oscillator | 96.61 | 12.08 |
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
GitLab Inc operates on an all-remote model. GitLab is a complete DevSecOps platform delivered as a single application. It operates in two competitive landscapes: DevOps point solutions and DevOps platforms. In terms of point solutions that are stitched together, GitLab's offering is substantially different in that it is one platform, one codebase, one interface, and a unified data model that spans the entire DevSecOps lifecycle. DevOps platforms, the principal competitor is Microsoft Corporation, following their acquisition of GitHub. GitLab is offered on both self-managed and software-as-a-service (SaaS) models. It is located in the United States, Europe, & the Asia Pacific. It focused on accelerating innovation & broadening the distribution of its platform to companies across the world.